June 3, 2025 10:32 AM EDT

Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100M

Jaimy Lee

Deputy Editor

Plus, news about Kamari Pharma, Leyden Labs, Kiora, Senju, Alto Neuroscience, Chase Therapeutics, Nxera Pharma, Neurocrine Biosciences, Aytu BioPharma and Fabre-Kramer:

On heels of pivotal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100M

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

At a crossroads, biotechs are passing on reverse mergers in 2025

GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Ve­ra re­draws the terms of up to $500M cred­it fa­cil­i­ty; Tre­vi aims to raise $100M

Deputy Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Vera redraws the terms of up to $500M credit facility; Trevi aims to raise $100M